Background And Objectives: The process of selecting blood donors is crucial for keeping the health of donors and ensuring the safety of the blood supply. However, it may create unpleasant feeling in those who are deferred. In this study, we aim to explore the return rates of Iranian deferred donors in comparison with eligible donors.

Materials And Methods: The study included all whole blood donors referred between March 2017 and March 2018, who experienced temporary deferral for any reason. Donors who successfully donated blood during this period were also part of the study. Participants were followed up until their next donation attempt, spanning 4.8 years after initial inclusion. Then odds of return and median return time for both deferred and eligible donors were calculated.

Results: From 993,824 volunteers, 733,153 (73.77%) were eligible and 192,332 (19.35%) temporary deferred. The return rate in the eligible and deferred donors was 74.77% vs. 51.77%, respectively (OR:2.78; 99%CI: 2.71-2.81). Odds of return among deferred regular (OR = 7.02, 99%CI:6.64-7.42), men (OR: 2.57, 99%CI:2.45-2.69), and over 45 years (OR: 1.15, 99% CI: 1.09-1.20), was higher than first-time, women, and younger donors. The median return time for eligible and deferred donors was 315 (99%CI: 313-316) and 1,467(99%CI: 1,412-1,524) days, respectively.

Conclusion: This study revealed the negative effect of deferral on the return rate, that led to a 23% reduction in the return of deferred donors. Avoiding unnecessary deferral through adherence to the standard operating procedure of donor selection and effective counselling which clarifies the purpose of deferral and encourages them to return after the deferral period ends are recommended.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tracli.2024.04.002DOI Listing

Publication Analysis

Top Keywords

deferred donors
16
return rate
12
blood donors
12
donors
11
return
10
deferred
9
odds return
8
median return
8
return time
8
eligible deferred
8

Similar Publications

Potential of emodepside for vector-borne disease control.

Malar J

January 2025

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Background: Emodepside is an anthelmintic used in veterinary medicine that is currently under investigation in human clinical trials for the treatment of soil-transmitted helminths and possibly Onchocerca volvulus. Emodepside targets the calcium-activated voltage-gated potassium slowpoke 1 (SLO-1) channels of presynaptic nerves of pharynx and body wall muscle cells of nematodes leading to paralysis, reduced locomotion and egg laying, starvation, and death. Emodepside also has activity against Drosophila melanogaster SLO-1 channels.

View Article and Find Full Text PDF

Notification of blood donors who test positive for transfusion-transmissible infections.

Vox Sang

January 2025

Donation and Policy Studies, Canadian Blood Services, Ottawa, Ontario, Canada.

Background And Objectives: Despite screening procedures, a few blood donors confirm positive for transfusion-transmissible infections and are deferred. Effective notification of laboratory results is essential to ensure that donors are advised of confirmed results and to seek medical care. Here we report results from post-notification interviews of Canadian Blood Services donors.

View Article and Find Full Text PDF

Background: The application of a temporary deferral when attempting to donate has a negative impact on retention. Little has been done to reduce the likelihood of a donor attending to donate, only to be found to be ineligible. The aim of this study was to determine the effectiveness of pre-screening donors when making an appointment, to prevent in-center deferrals.

View Article and Find Full Text PDF

[Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management].

Zhonghua Xue Ye Xue Za Zhi

November 2024

Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou 510515, China.

At present, the world has entered the normalization stage of coronavirus disease 2019 (COVID-19) management. COVID-19 continues to affect patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for a long period. The author discussed the possible effect of COVID-19 on HSCT strategy and prognosis during this period based on literature reports.

View Article and Find Full Text PDF
Article Synopsis
  • Pedicle ossification is a rare complication that can occur after using a fibular free flap (FFF) for mandibular reconstruction, potentially simulating tumor recurrence and leading to diagnostic challenges.
  • A case study of a 38-year-old male with squamous cell carcinoma highlighted how postoperative complications led to the need for FFF reconstruction, and over 4 years, CT scans showed ossification in the flap's vascular pedicle, yet the patient remained asymptomatic.
  • Regular imaging and clinical assessments are key to distinguishing ossification from tumor recurrence, with surgery usually only considered if symptoms arise.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!